• Mutation; HGNC; HGNC:4390; GNAQ; Simple; p.Gln209Pro (c.626A>C); ClinVar=VCV000375957; Zygosity=Heterozygous (PubMed=24354797; PubMed=25952648).
  

PubMed=24354797; DOI=10.1111/pcmr.12206
Yoshida M., Selvan S.R., McCue P.A., DeAngelis T., Baserga R., Fujii A., Rui H., Mastrangelo M.J., Sato T.
Expression of insulin-like growth factor-1 receptor in metastatic uveal melanoma and implications for potential autocrine and paracrine tumor cell growth.
Pigment Cell Melanoma Res. 27:297-308(2014)

PubMed=25952648; DOI=10.1158/0008-5472.CAN-15-0370; PMCID=PMC4490069
Cheng H.-Y., Terai M., Kageyama K., Ozaki S., McCue P.A., Sato T., Aplin A.E.
Paracrine effect of NRG1 and HGF drives resistance to MEK inhibitors in metastatic uveal melanoma.
Cancer Res. 75:2737-2748(2015)

PubMed=26613897; DOI=10.1016/j.ajpath.2015.09.011; PMCID=PMC4715216
Ozaki S., Vuyyuru R., Kageyama K., Terai M., Ohara M., Cheng H.-Y., Manser T.L., Mastrangelo M.J., Aplin A.E., Sato T.
Establishment and characterization of orthotopic mouse models for human uveal melanoma hepatic colonization.
Am. J. Pathol. 186:43-56(2016)

PubMed=32430489; DOI=10.1158/1535-7163.MCT-19-1016; PMCID=PMC7415561
Teh J.L.F., Purwin T.J., Han A., Chua V., Patel P., Baqai U., Liao C., Bechtel N., Sato T., Davies M.A., Aguirre-Ghiso J.A., Aplin A.E.
Metabolic adaptations to MEK and CDK4/6 cotargeting in uveal melanoma.
Mol. Cancer Ther. 19:1719-1726(2020)